Evidence map›Paper›PMID 36261374›Full record

ArticleInternal medicine (Tokyo, Japan)2023

A Hepatitis B Virus Reactivation Case Potentially Triggered by the Onset of Diffuse Large B Cell Lymphoma.

Kentaro Sato, Hidemichi Imamura, Yu Watahiki, Hiromasa Hazama, Takeaki Hashimoto, Shinji Mukae, Hiromasa Ohhira

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Kentaro SatoDepartment of Gastroenterology, Aizu Medical Center, Japan.
Hidemichi ImamuraDepartment of Gastroenterology, Ohta Nishinouchi Hospital, Japan.
Yu WatahikiDepartment of Gastroenterology, Ohta Nishinouchi Hospital, Japan.
Hiromasa HazamaDepartment of Gastroenterology, Ohta Nishinouchi Hospital, Japan.
Takeaki HashimotoDepartment of Gastroenterology, Ohta Nishinouchi Hospital, Japan.
Shinji MukaeDepartment of Gastroenterology, Ohta Nishinouchi Hospital, Japan.
Hiromasa OhhiraDepartment of Gastroenterology, Fukushima Medical University School of Medicine, Japan.
Ohta Nishinouchi Hospital · JPFukushima Medical University · JPUniversity of Aizu · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An 81-year-old man underwent rituximab-containing chemotherapy for chronic lymphocytic leukemia (CLL). Thirteen years after his last chemotherapy, he was diagnosed with hepatitis B virus (HBV) reactivation. He was then treated with entecavir, and improvement was seen in his liver injury. He developed diffuse large B cell lymphoma (DLBCL) after improvement in his hepatitis. Despite chemotherapy, he contracted the coronavirus disease 2019 (COVID-19) and died of COVID-19. We suspect that HBV reactivation was triggered by DLBCL. When HBV reactivation occurs a long time after chemotherapy has concluded, the onset of DLBCL should be considered.

Indexed as

COVID-19Hepatitis BLymphoma, Large B-Cell, DiffuseAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsHepatitis B Surface AntigensHepatitis B virusHumansMaleRituximabVirus ActivationHepatitis B Surface AntigensRituximabdiffuse large B cell lymphomahepatitis B virus reactivation

Identifiers

PMID36261374
PMCPMC10293001
OpenAlexW4306720341

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.